AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05133908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBTi-ADHD
Description: The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
Study NCT06127225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proliverenol
Description: 1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
Study NCT04785352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Description: One egg per day for six months
Study NCT04785352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grandi Byen
Description: Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
Study NCT06439784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body SPECT/CT
Description: Patient will unergo a whole body SPECT/CT in treatment position
Study NCT04802590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg
Description: 560mg/d continuously from C1D2 to end C24
Study NCT05619822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + A comprehensive third-generation intervention
Description: This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future
Study NCT05619822 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: Treatment as usual
Study NCT04802590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 10 MG Oral Tablet [Venclexta]
Description: 20mg/d from C2D1 to C2D7
Study NCT04802590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 50 MG Oral Tablet [Venclexta]
Description: 50mg/d from C2D8 to C2D14
Study NCT04802590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 MG Oral Tablet [Venclexta]
Description: 100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
Study NCT06127225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo caplets of Proliverenol
Description: 2 caplets of Proliverenol Placebo daily
Study NCT05886816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoquinone/mitoquinol mesylate
Description: Mitochondrial antioxidant
Study NCT05886816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study NCT04923815 — intervention group
Intervention type: DEVICE
Intervention: THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter
Description: THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.
Study NCT05686486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi inspired gymnastics
Description: The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance.
Study NCT05686486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi inspired gymnastics
Description: The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance.
Study NCT06342609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: 0.5mg per day of Colchicine orally administered
Study NCT06342609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: 0.5mg per day of Colchicine orally administered
Study NCT05440565 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecal immunochemical test
Description: Fecal immunochemical test can concentrate the high-risk population.
Study NCT04709471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will reduce their nicotine intake
Study NCT04709471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juul e-cigarette
Description: Participants will switch to Juul pods containing less nicotine
Study NCT04709471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction
Description: Participants will reduce the number of Juul pods that they use
Study NCT05943977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102 DMID
Description: 130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
Study NCT05943977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102 OMID
Description: 130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
Study NCT05943977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Description: On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
Study NCT05440565 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: APCS score
Description: APCS score can concentrate the high-risk population.
Study NCT05604586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
Study NCT05700136 — intervention group
Intervention type: BEHAVIORAL
Intervention: MOMENT
Description: Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
Study NCT06468202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Participants will be assigned to 81mg Aspirin
Study NCT06468202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Participants will be assigned to 162mg Aspirin
Study NCT05970614 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eye masks and ear plugs
Description: Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
Study NCT04738838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
Study NCT04738838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Intranasal treatment with placebo via nasal spray
Study NCT03998592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pyogenes vaccine (50 µg)
Description: Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
Study NCT03998592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pyogenes vaccine (100 µg)
Description: Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
Study NCT03998592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pyogenes vaccine (200 µg)
Description: Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
Study NCT03998592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo without active component
Study NCT06503003 — intervention group
Intervention type: DEVICE
Intervention: Leonardo® Diode laser
Description: The intervention involves non-ablative dual-wavelength diode laser therapy for treating Genitourinary Syndrome of Menopause (GSM). This includes three monthly sessions of the Leonardo® Diode laser (Biolitec®), with wavelengths of 980 nm and 1470 nm, delivering 8 pulses per centimeter along the vaginal canal, using local lidocaine gel as an anesthetic. Evaluations are conducted at baseline, 3 months, and 6 months post-treatment.
Study NCT05450991 — intervention group
Intervention type: PROCEDURE
Intervention: Pull through
Description: Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included
Study NCT06371417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY121
Description: Injection
Study NCT05080192 — intervention group
Intervention type: DRUG
Intervention: Fenofibrate
Description: 145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
Study NCT05080192 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Matching placebo (once/day) for 10 days
Study NCT06303986 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neomonki
Description: The Neomonki is a monitoring kit for hospital use in neonates with Neonatal Abstinence Syndrome (NAS).
Study NCT05074498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: intravenous infusion
Study NCT05074498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion
Study NCT04944693 — intervention group
Intervention type: OTHER
Intervention: Different ATS values.
Description: Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts.
Study NCT05037656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based curriculum
Description: Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
Study NCT05978609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candonilimab
Description: Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
Study NCT05978609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
Study NCT05978609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
Study NCT05805059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact Lens (stenfilcon A)
Description: one week wear
Study NCT05805059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact Lens (senofilcon A)
Description: one week of wear
Study NCT05159596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Technology System
Description: Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
Study NCT05159596 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Limited In-Home Technology
Description: Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
Study NCT06476275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/Texas/71/2017 (H3N2)
Description: Virus will be administered intranasally
Study NCT06476275 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham placebo
Description: Placebo will be administered intranasally
Study NCT04451590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-based simulation
Description: Participants will experience a novel interactive and immersive VR full size trauma bay with an adult patient and healthcare professionals. Immersed in the environment, learners undertake the decision-making steps in managing the medical care for a patient with an airway injury. Learners are first given the case scenario from which they form their own learning goals/plans. They then navigate through the scenario that will provide feedback depending on their actions in the form of either the patient's hemodynamic changes or prompts from healthcare avatars in the scenario. These feedback processes are built-in and designed to promote reflection and reorganization of the learner's decision-making strategies. As learning progresses, fewer prompts will be given. At the end of the scenario, evaluation algorithms pre-programmed into the VR-based simulation will be displayed.
Study NCT04451590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mannequin-based simulation
Description: Participants will experience a mannequin-based scenario practice which is the current gold standard in medical education. The trauma airway management scenario will match the VR environment and sequence of events.
Study NCT06637826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quaternary Ammonium Compound Disinfectants
Description: Participants are instructed to use quaternary ammonium compound disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation.
Study NCT06637826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-based Disinfectants
Description: Participants are instructed to use alcohol-based disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation.
Study NCT05769218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHORUS+
Description: The CHORUS+ intervention will include a baseline interview with a peer recovery coach to encourage uptake of HIV PrEP (pre-exposure prophylaxis) and medications for opioid use disorder (MOUD) through motivational interviewing (MI). Participants will also be offered HIV self-testing on the day of recruitment, HIV PrEP (if they are HIV negative) and MOUD. Participants will then receive peer coaching for 6 months to increase adherence to PrEP and or MOUD.
Study NCT05769218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Normal protocols for care of participants who inject opioids will be followed.
Study NCT05905458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950 tablets
Description: HRS9950 tablets, oral, once a week, low dose
Study NCT05905458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950 tablets
Description: HRS9950 tablets, oral, once a week, high dose
Study NCT05905458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9950 placebo tablets
Description: HRS9950 placebo tablets, oral, once a week.
Study NCT05034185 — intervention group
Intervention type: DEVICE
Intervention: Computer-aided diagnosis (CADx) support tool
Description: The CADx support tool operates when the Clinician switches the preconfigured CAD EYE function on using a button on the controller while the scope system is in BLI mode. This is performed after the Clinician first makes an optical prediction of polyp histology using IEE as described. The CADx support tool will make a prediction of polyp histology as hyperplastic or neoplastic.
Study NCT06527105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye masks and ear plugs
Description: Eye masks and ear plugs given during sleeping time in Icu After cardiac surgery
Study NCT04203433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLX105-DMP
Description: 1mg applied to target lesion
Study NCT04968795 — intervention group
Intervention type: OTHER
Intervention: Heartfulness Meditation
Description: A four-week Heartfulness Wellness seminar, where people are exposed to Heartfulness Meditation and its meditation tools. Participants experience: Heartfulness Guided Relaxation, Heartfulness Meditation and Heartfulness Unwinding/Rejuvenation Technique.
Study NCT04502719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nutritional screening.
Description: Nutritional screening with the RFH-NPT and LDUST questionnaires.
Study NCT05247840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: uroflowmetry
Description: Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.